# eeg monitoring Market Research Report - Europe

**Generated on:** 2025-11-09 20:07:32.210790  
**Industry:** eeg monitoring  
**Geography:** Europe  
**Details:** eeg monitoring in Europe, including reimbursement scheme per country, key competitors, relevant regulations. Also ouline innovation, especially AI and EEG foundational models.

---

# Europe’s EEG Monitoring Boom: 10.1% CAGR Meets AI-Driven Disruption

## Executive Summary

The European Electroencephalography (EEG) monitoring market is undergoing a profound transformation, characterized by robust growth, a rapid shift toward portable and AI-enabled technologies, and a complex, fragmented reimbursement and regulatory landscape. Valued at approximately **USD 351.1 million in 2024**, the market is projected to nearly double, reaching **USD 625.8 million by 2030** at a compound annual growth rate (CAGR) of **10.11%** [1]. This expansion is fueled by the escalating burden of neurological disorders, an aging population, and workflow pressures in healthcare systems. However, success is not guaranteed; it hinges on navigating disparate country-level reimbursement schemes, stringent new regulations, and the technical challenges of data governance. This report provides a comprehensive strategic analysis of the market, outlining the key trends, competitive dynamics, and actionable recommendations for device manufacturers, healthcare providers, and investors.

### Clinical Demand Outpaces Budgets, Creating an Opening for Efficiency-Driven Solutions
Europe's neurological disease burden is immense, with **7 million dementia cases in 2025** projected to double by 2030 and over **6 million people** living with epilepsy [2] [3]. This demographic pressure is creating a demand for EEG diagnostics that far outstrips the capacity and budgets of many national health systems. Vendors that can deliver solutions offering clear efficiency gains—such as AI-powered triage software bundled with low-capital-expenditure portable devices—are best positioned to unlock this latent demand without straining existing DRG budgets.

### The Shift to Portable and Wearable Devices Accelerates
The market is decisively moving away from traditional, stationary systems. The portable and wearable device segment is projected to grow at a CAGR of **11.23%**, significantly faster than the market average [4]. This shift is driven by the rising need for remote patient monitoring, home-based healthcare, and consumer wellness applications [1]. In 2024, portable EEG devices already command a **61%** market share [5]. To capitalize on this trend, manufacturers must prioritize product roadmaps for battery-powered, wireless, and user-friendly devices, while proactively engaging with national payers to secure reimbursement codes for home and ambulatory monitoring.

### AI Moves From Research Pilot to Reimbursable Clinical Tool
Artificial Intelligence is no longer a theoretical enhancement but a tangible clinical and commercial driver. Natus Medical's CE-marked **autoSCORE** AI, trained on over 30,000 EEGs from Norway and Denmark, has demonstrated diagnostic accuracy comparable to human experts and is now commercially available [6] [7]. Similarly, NeuroCare’s AI tool for early Alzheimer's detection launched in Germany in May 2024, securing research funding from sickness funds [8]. This signals a critical inflection point: hospitals should now include AI capabilities in procurement requirements, and payers have a basis to justify add-on payments tied to proven efficiency gains, such as reduced interpretation time.

### Reimbursement Patchwork Remains the Primary Market Gatekeeper
The value of an EEG procedure varies dramatically across Europe, creating a complex patchwork that dictates market access and profitability. A 24-hour ambulatory Holter EEG is reimbursed at **€209.95** in France under CCAM code **AAQP002**, while the UK private tariff for a similar procedure is **£315** [9]. Meanwhile, other countries lack dedicated codes for advanced or ambulatory monitoring. This disparity makes a one-size-fits-all strategy unviable. Success requires granular, country-by-country market access plans, leveraging national innovation pathways like Germany's NUB process or France's new add-on device recommendations.

### Regulation Tightens but Also Clarifies the Path for AI
The European regulatory environment is becoming more stringent but also more predictable. Most clinical EEG hardware is classified as **Class IIa** under the EU Medical Device Regulation (MDR), with accessories like electrodes as Class I [10] [11]. The landmark EU AI Act, with obligations for high-risk systems applying around **May 2028** for medical devices, will classify most diagnostic EEG-AI software as "high-risk" [12]. However, it also provides a streamlined path by allowing a single technical documentation file to satisfy both MDR and AI Act requirements, potentially reducing duplicative effort for manufacturers who plan for integrated compliance from the outset [12].

### Data Governance and Interoperability Become Critical Bottlenecks
As EEG systems become more connected, data governance has emerged as a primary hurdle. Research has demonstrated that individuals can be re-identified from supposedly "anonymized" EEG data, raising significant GDPR concerns [13] [14]. Furthermore, the successful 2020 implementation of the **DICOM Neurophysiology standard** in Vienna, which replaced proprietary formats and integrated with hospital EHRs, sets a new benchmark for interoperability [15]. Vendors must now ship devices with built-in pseudonymization tools and support for modern standards like DICOM to pass hospital IT due-diligence and procurement checks.

### Skills Shortages Create a White-Space for Service-Based Models
A chronic shortage of trained neuro-diagnostic technologists in several countries, including Spain and Italy, creates significant backlogs and underutilization of equipment [3]. This operational pain point creates a strategic opening for innovative commercial models. Vendors offering "service-as-a-subscription" packages—bundling the EEG device with remote technologist support and AI-assisted interpretation—can win tenders where staffing, not capital, is the primary constraint.

### EEG Foundation Models Show Promise but Require Data Diversity
The development of large, pre-trained EEG foundation models (EEG-FMs) represents the next frontier in EEG-AI, promising a leap in generalizability and performance. However, a 2025 review noted that most current models are trained on a limited number of public datasets, many of which are US-based (e.g., the TUH EEG Corpus) [16]. An external validation of the SCORE-AI model on a new European cohort showed robust performance, but the broader challenge of dataset bias remains [17]. Realizing the full potential of EEG-FMs will require pan-European, consortium-level data-sharing initiatives, such as those facilitated by **EBRAINS**, to build models that payers and clinicians can trust across diverse populations [18].

## 1. Market Size & Growth: A €626 Million Market by 2030

The European EEG monitoring market is on a trajectory of robust and sustained growth, driven by a convergence of clinical need, technological innovation, and evolving care models. The market was valued at approximately **USD 322.7 million in 2023** and is forecast to reach **USD 351.1 million in 2024** [1]. Projecting forward, consistent double-digit growth is expected, with the market anticipated to reach **USD 625.8 million by 2030**, reflecting a strong CAGR of **10.11%** [1]. Other analyses support this positive outlook, with some projecting the market could reach as high as **USD 847.08 million by 2033** [19]. Europe is a significant player globally, expected to account for **26%** of the worldwide EEG device market in 2025 [8].

### 1.1. Segment Breakout: Portables and Multichannel Devices Lead the Charge

The market's growth is not uniform; specific segments are expanding at a much faster rate, signaling a clear shift in clinical practice and technology adoption. Portable and wearable devices are the standout growth category, while 32-channel systems remain the workhorse of the industry.

| Market Segment | 2023/2024 Share | Key Growth Drivers & Insights |
| :--- | :--- | :--- |
| **By Modality: Portable Devices** | 61% share in 2024 [5] | **Fastest-growing segment** [1]. Driven by rising demand for remote patient monitoring, home-based healthcare, and telehealth applications. Technological advancements have made these devices more compact, user-friendly, and capable [1]. |
| **By Modality: Standalone Devices** | 71.9% share in 2023 [1] | Continue to dominate due to cost-effectiveness, user-friendly interfaces, and established presence in hospitals and clinics. They are the standard for in-patient and acute care settings [1] [19]. |
| **By Channel Count: 32-Channel EEG** | 27.7% share in 2023 [1] | Dominant segment due to its balance of superior spatial resolution for precise diagnosis and versatility across hospitals, clinics, and research labs [1]. |
| **By Channel Count: Multichannel EEG** | Fastest-growing segment [1] | Growth fueled by technological advancements making high-channel-count systems more accessible and their integration with other modalities like fMRI and MEG [1]. |
| **By Application: Disease Diagnosis** | 32.0% share in 2023 [1] | Largest application segment. EEG is a cornerstone for diagnosing epilepsy, sleep disorders, and specific brain injuries, which are all on the rise [1] [19]. |
| **By End-User: Hospitals** | 67.8% share in 2023 [1] | The primary setting for EEG procedures, with high patient volumes across neurology, ICU, and emergency departments [1]. |
| **By End-User: Diagnostic Centers** | Fastest-growing segment [1] | Growth is driven by the increasing incidence of neurological disorders and a trend towards specialized outpatient diagnostic services [1]. |

The data clearly indicates a dual market: a large, stable base of standalone systems in hospitals, complemented by a rapidly expanding market for portable devices used in remote and home settings.

### 1.2. Country Contributions: Germany Dominates, but Growth is Pan-European

While Germany is the undisputed leader, the EEG market is healthy across the continent, with different national priorities shaping adoption patterns.

| Country | 2024 Market Share (Europe) | Key Characteristics & Trends |
| :--- | :--- | :--- |
| **Germany** | **39.2%** [2] | Largest market, driven by robust hospital infrastructure, high healthcare spending, and early adoption of advanced neurodiagnostics. Home to major research and innovation hubs [19] [2]. |
| **United Kingdom** | Not specified | Rapid adoption of wearable EEGs for sleep and mental health. NHS pilot projects are actively promoting remote EEG monitoring for epilepsy patients [3]. |
| **France** | Not specified | Focus on mid-tier (25- and 32-channel) systems for regional hospitals. Government subsidies and telehealth initiatives are expanding access in rural areas [19]. Expected to be the fastest-growing country market [5]. |
| **Italy** | Not specified | Market expansion is concentrated in independent diagnostic centers and neurology clinics, driven by a large geriatric population and the need for dementia diagnostics [3]. |
| **Spain** | Not specified | Notable investment in pediatric neurology and autism research using EEG. The private clinic sector is growing, partly due to health tourism [19]. |
| **Nordic Countries** | Not specified | Leaders in tele-neurology and the integration of cloud-based EEG monitoring, supported by high research funding for neurotechnology [3]. |

Germany's market leadership is a result of its structural advantages, while growth in other nations is being shaped by specific healthcare policies and clinical priorities.

### 1.3. Scenario Forecasts 2025-2030: Reimbursement is the Key Variable

The market's trajectory to **~€626M by 2030** is robust, but the pace of growth is highly sensitive to regulatory and reimbursement developments, particularly for innovative portable and AI-driven solutions.

* **Base Case (10.1% CAGR):** Assumes gradual, country-by-country reimbursement updates for ambulatory and AI-assisted EEG, with MDR and AI Act compliance proceeding as scheduled.
* **Bull Case (12-14% CAGR):** Triggered by a harmonized EU-level reimbursement pathway for digital health technologies or fast-track approval and funding for AI diagnostics in major markets (Germany, France, UK). This would rapidly accelerate the adoption of portable and AI-enabled systems.
* **Bear Case (5-7% CAGR):** Could result from significant delays in Notified Body capacity for MDR/AI Act certification, widespread rejection of NUB/innovation funding applications, or stricter data privacy interpretations that stifle cloud-based AI services.

## 2. Demand Drivers & Restraints

The powerful tailwinds of demographic change and clinical need are propelling the EEG market forward, though this momentum is tempered by significant structural friction from reimbursement and regulatory systems.

### 2.1. Unrelenting Disease Burden Fuels Demand
The primary driver is the sheer scale of neurological disease in Europe. Over **220 million people** are affected by neurological conditions annually [3]. The prevalence of Alzheimer's disease is set to double from **7 million to 14 million by 2030**, and Germany alone expects its dementia population to grow from **1.8 million in 2021 to 2.8 million by 2050** [8] [2]. This, combined with Europe's aging population—nearly **21%** are over 65—creates a non-negotiable clinical demand for effective and accessible diagnostic tools like EEG [3].

### 2.2. Workflow Pressures and Home Monitoring Push for Innovation
Healthcare systems are under immense pressure, creating a strong pull for technologies that improve efficiency and shift care out of the hospital. The shortage of skilled EEG technologists, particularly in countries like Spain and Italy, leads to diagnostic backlogs and underutilization of equipment [3]. This creates a clear business case for AI-powered interpretation tools that reduce clinician reading time and for portable devices that enable remote and home-based monitoring. The rapid growth in Remote Patient Monitoring (RPM) adoption, especially in Germany and the UK, is a major catalyst for the portable EEG segment [20].

### 2.3. Reimbursement and Regulatory Friction Points Act as Brakes
Despite the clear need, significant barriers restrain market growth.
* **Reimbursement Hurdles:** Securing reimbursement for new technologies is a primary challenge. Stringent reimbursement laws and the lack of dedicated codes for innovative procedures deter practitioners and slow adoption [8].
* **Regulatory Complexity:** Navigating the dual requirements of the EU MDR and the upcoming AI Act is a complex and costly endeavor for manufacturers. The average approval time for a Class IIa device under MDR is **12-18 months** [3].
* **Data Privacy:** GDPR compliance is a major concern, especially for cloud-connected and AI-enabled systems. A **25%** increase in healthcare data breaches in 2023 has heightened scrutiny, with some clinics reportedly delaying adoption of AI-EEG systems due to these concerns [3].
* **High Cost:** The high cost of advanced EEG systems, particularly those with integrated AI, remains a barrier to widespread adoption in budget-constrained public healthcare systems [3].

## 3. Competitive Landscape: Incumbents Face Disruption from AI-First Challengers

The European EEG market is dominated by a handful of established medical device giants, but the landscape is being reshaped by a dynamic cohort of smaller, more agile innovators focused on AI, portability, and niche applications. Mergers and acquisitions are a key strategy, as seen in **Aditxt's acquisition of Brain Scientific's EEG portfolio in January 2024** and **Natus Medical's full acquisition of AI specialist Holberg EEG in September 2025** [21] [3].

### 3.1. Incumbent Scorecard: Established Leaders Defend Market Share

Four major players—Natus Medical, Nihon Kohden, Medtronic, and Compumedics—leverage their extensive product portfolios, large European footprints, and established hospital relationships to maintain a dominant market position. However, some are facing headwinds; Natus, for example, saw a **6% revenue decline in 2023** due to softer EEG equipment sales, though it projects a recovery in 2025 driven by new product launches [22].

| Company | Key Product Lines & Strategy | European Presence & Regulatory Status |
| :--- | :--- | :--- |
| **Natus Medical** (USA) | Comprehensive portfolio including NeuroWorks®, Nicolet® systems for routine EEG, LTM, and ICU. Strategy is shifting towards AI with the acquisition of Holberg EEG and launch of **autoSCORE** AI and the **BrainWatch** point-of-care system [23] [21] [24]. | Direct offices across Europe. Products are CE-marked; autoSCORE has both CE mark and FDA clearance [25] [6]. |
| **Nihon Kohden** (Japan) | High global market share in electroencephalographs. Offers a range of clinical EEG systems and an innovative EEG headset for ICU use. Strengthening its neurology business in Europe, with sales growth in Germany and Italy [26]. | Strong European presence with subsidiaries in Germany, France, UK, Italy, and Spain. Products are CE-marked [26] [27]. |
| **Medtronic** (Ireland) | Focus on brain monitoring within a broader patient monitoring portfolio, including the BIS™ system for monitoring depth of anesthesia using processed EEG [28]. Recently achieved EU MDR CE Mark for its **BrainSense™ aDBS** system in January 2025 [29]. | Extensive presence in over 150 countries, including a major European base. Products comply with EU MDR [29] [30]. |
| **Compumedics** (Australia) | Offers a range of neurodiagnostic and sleep diagnostic systems. Active in the European market, often cited as a key competitor [1]. | Operates through a network of distributors across Europe. Products are CE-marked. |
| **Brain Products GmbH** (Germany) | Specializes in high-end EEG hardware and software for neurophysiological research. A key player in the European research market [1]. | Headquartered in Germany with a strong European and global distribution network. |

### 3.2. Challenger Matrix: Innovators Target Niche Gaps with AI and Portability

A vibrant ecosystem of startups and specialized firms is challenging the status quo by focusing on portability, dry-electrode technology, and AI-driven analytics. These companies often target specific clinical needs like point-of-care seizure detection or home-based sleep studies.

| Company | Unique Selling Proposition (USP) & Technology | European Status & Go-to-Market Strategy |
| :--- | :--- | :--- |
| **Ceribell, Inc.** (USA) | World's first brain monitor for point-of-care seizure detection. Focus on rapid EEG for emergency and ICU settings. Recognized as a top innovative company in 2023 [1]. | CE-marked. Targeting hospital emergency departments and ICUs, addressing the critical need for rapid seizure triage. |
| **Neuroelectrics** (Spain) | Wireless, medical-grade Enobio EEG systems (8, 20, 32 channels) with dry and wet electrodes for research and clinical use. Focus on high-definition brain stimulation and monitoring [31]. | Products are CE-marked and compliant with EU MDR transition rules [32] [33]. Partnering with analytics firms like Neuronostics to offer integrated solutions for clinical trials [34]. |
| **mBrainTrain** (Serbia) | Fully portable, head-worn EEG systems (Smarting PRO series) for research, including use on the International Space Station. Focus on mobile, real-world data capture with real-time artifact removal [35]. | Recognized as Portable EEG System Company of the Year in Europe for 2025 [36]. Primarily targets the research market. |
| **BrainTrip** (Malta) | AI-powered NeuroAI platform with a CE-marked tool (CogniScore) for rapid, non-invasive dementia screening from a 30-minute EEG, claiming ~95% accuracy [37]. | Scaling in Europe with support from EIT Health for regulatory and clinical integration strategy. Targets outpatient clinics and primary care for early cognitive assessment [37]. |
| **Kvikna Medical (Stratus)** (Iceland/USA) | Stratus EEG software system for acquisition, display, and analysis, with a dedicated secure cloud solution. Offers a portable solution for home-based video EEG monitoring [38] [39]. | Stratus EEG software is one of the first to achieve Class IIa certification under the full EU MDR (August 2023) [38]. |

## 4. Country-by-Country Reimbursement Playbook

Navigating Europe's fragmented reimbursement landscape is the single most critical factor for commercial success in the EEG market. Payment mechanisms, coding systems, and tariff levels vary significantly, requiring a tailored strategy for each country. Below is a playbook summarizing the reimbursement environment in key European markets.

### 4.1. Germany: Navigating the DRG-EBM Divide

* **Framework:** A dual system exists. Inpatient services are reimbursed via the **G-DRG (German Diagnosis Related Groups)** system, a fee-per-case model managed by InEK [40] [41]. Outpatient services are covered by the **EBM (Uniform Evaluation Standard)** catalog, a fee-for-service schedule managed by the KBV [42].
* **Inpatient Coding (OPS & G-DRG):** Procedures are coded using **OPS (Operationen- und Prozedurenschlüssel)**. Key EEG codes include:
 * **1-207.0:** Routine-EEG
 * **1-207.2:** Video-EEG (≥ 24 hours)
 * **1-210:** Non-invasive Video-EEG intensive diagnostics for epilepsy
 * **8-920:** EEG-Monitoring in ICU (> 24 hours) [43]
 * These OPS codes influence assignment to specific DRGs, such as **B76B/D/E** for seizures, where the use of EEG is an explicit grouping criterion [44].
* **Outpatient Coding (EBM):** While specific EBM code numbers for EEG were not found in the research, the EBM catalog governs all outpatient billing [42]. The Q2 2025 EBM revision focused on digital health apps and consultations, indicating a pathway for new technologies but no specific EEG changes were noted [45].
* **Innovation Pathway (NUB):** The **NUB (Neue Untersuchungs- und Behandlungsmethoden)** process allows hospitals to apply for temporary, supplementary "on-top" payments for innovative and costly technologies not yet adequately covered by a DRG [41]. Hospitals apply annually to InEK, and if approved, negotiate the payment amount with local payers [46] [41]. While no EEG-specific NUBs were approved for 2025, this remains the primary path for introducing high-cost innovations like AI software or novel devices into the inpatient setting [47].

### 4.2. United Kingdom: OPCS Codes and the NHS Payment Scheme

* **Framework:** The NHS in England uses the **NHS Payment Scheme** (which replaced the National Tariff in 2023) [48]. Procedures are coded using **OPCS-4**, and activity is grouped into **Healthcare Resource Groups (HRGs)** [49].
* **Procedure Codes (OPCS-4):**
 * **A84.1 Electroencephalography NEC:** Standard EEG, typically an outpatient procedure [50].
 * **U22.1 Electroencephalograph telemetry:** Specialized long-term video-EEG, usually requiring a multi-day hospital stay (3-21 days). This code is an exception and **must always be coded** for both inpatient and outpatient episodes [50].
 * **A84.7 Sleep studies NEC:** Includes full polysomnography with EEG [50].
* **Tariffs & Coverage:** Many diagnostic tests, including standard EEG, are often considered "unbundled" or do not have a national price for outpatient attendances (e.g., TFC 19 for 'EEG, EMG or Nerve Conduction Studies') [51]. Payment is therefore subject to local agreement. For admitted patient care, payment is spell-based, with long-stay payments applicable if a patient's stay exceeds the HRG-specific "trim point" [52].
* **Private Market:** A 2024 tariff schedule from one NHS Trust listed a private patient price of **£315** for EEG, Sleep, EMG, and Ambulatory Monitoring [9].

### 4.3. France: CCAM Codes and OPTAM Tariffs

* **Framework:** Procedures are coded using the **CCAM (Classification Commune des Actes Médicaux)** classification. Tariffs vary based on whether the physician adheres to the **OPTAM** (Option de Pratique Tarifaire Maîtrisée) agreement, which limits balance billing.
* **Procedure Codes (CCAM):**
 * **AAQP002:** Covers 'Continuous ambulatory electroencephalography on 8 derivations or more, for at least 24 hours [Holter EEG]'. The tariff is **€209.95** for OPTAM physicians and **€145.97** for non-OPTAM [53].
* **Innovation Pathway:** In July 2025, the national health authority (HAS) released recommendations regarding add-on reimbursement for medical devices, signaling a potential new pathway for innovative EEG technologies to secure funding outside of standard procedure tariffs [53]. The CCAM nomenclature is regularly updated, with version 77 taking effect in January 2025 [54].

### 4.4. Belgium: Detailed INAMI/RIZIV Nomenclature

* **Framework:** The National Institute for Health and Disability Insurance (INAMI/RIZIV) manages the nomenclature of medical procedures and their reimbursement.
* **Procedure Codes (NIHDI):** A 2025 INAMI-RIZIV report on EEG practice variations provides specific codes [55]:
 * **477131 / 477142:** "Electroencéphalographie" (Standard EEG). Value: **K59**. This code accounts for **95.5%** of EEG services.
 * **477411 / 477422:** Continuous ambulatory EEG (Holter type, ≥ 24 hours, ≥ 4 derivations). Value: **K150**. Accounts for **1.7%** of services.
 * **477610 / 477621:** Quantitative EEG (≥ 19 channels). Value: **K59**. Accounts for **2.8%** of services.
* **Expenditure:** Total annual expenditure for these EEG services in Belgium was **€29.4 million** in 2024, with an average cost per patient of **€107.74** [55].

### 4.5. Netherlands: DRGs and Supplementary Payments

* **Framework:** Specialist medical care is reimbursed via a DRG system (**DBC - Diagnose Behandeling Combinatie**). The Dutch Healthcare Authority (NZa) manages the system.
* **Coding & Tariffs:** Specific DBCs for EEG were not identified, but the NZa's 2026 DRG package (RZ26a) includes updates affecting neurology and neurosurgery, with new procedure codes and supplementary payments (OZPs) [56]. A specific reimbursement code for telemonitoring, **NZA 039133**, exists with a rate of **€168.06 to €184.87** every 120 days, which could be applicable to remote EEG services [57].
* **Innovation Pathway:** The NZa has a policy framework for small-scale experiments to introduce innovations, and the Dutch Healthcare Institute (ZIN) is actively developing coverage positions in neurology [58] [59].

### 4.6. Other Key Markets: A Patchwork of Systems

* **Switzerland:** Uses **SwissDRG** for inpatient care and **TARMED** for outpatient services. The 2025 version of SwissDRG has been released, but specific EEG codes or tariffs were not identified [60].
* **Austria:** Inpatient care is reimbursed via the **LKF (Leistungsorientierte Krankenanstaltenfinanzierung)** DRG model. The final 2026 LKF model includes 32 new procedure codes, with some related to e-health, but no new DRGs were introduced [61].
* **Poland:** The National Health Fund (NFZ) manages reimbursement. Digital health solutions are generally not reimbursable, with exceptions for tele-consultations created during the pandemic [62].
* **Spain:** The national Common Package of Benefits was updated in May 2025 to explicitly include electromyography and other diagnostic procedures accessible from primary care, but EEG was not specifically mentioned [63]. Reimbursement is highly decentralized to the Autonomous Communities.
* **Italy:** New national **LEA (Essential Levels of Care)** tariffs for outpatient specialist care were approved in November 2024 and are set to take effect on **December 30, 2024**, revising 35% of all tariffs. However, their implementation has been repeatedly postponed, and the Minister of Health has already called for further revisions, indicating instability [64].
* **Nordic Countries (Sweden, Norway, Denmark):** These countries largely use the **NordDRG** system. The 2025 Swedish NordDRG system includes a base rate of **88,061 SEK** to be multiplied by DRG cost weights to determine tariffs [65]. Norway's preliminary 2026 DRG system shows no significant changes [65].

## 5. Regulatory & Data-Governance Landscape

The European regulatory framework for medical devices is undergoing a significant transformation, with the full implementation of the EU Medical Device Regulation (MDR) and the introduction of the EU AI Act. This convergence creates a higher compliance bar for all manufacturers, especially those incorporating software and AI.

### 5.1. MDR Classification and Notified Body Bottlenecks
Under the EU MDR (2017/745), EEG devices are subject to a risk-based classification system.
* **EEG Hardware:** Patient monitoring equipment, including most EEG systems, is typically classified as **Class IIa** (moderate risk) [10] [11].
* **Accessories:** Non-invasive electrodes are classified as **Class I** (lowest risk) [10] [66].
* **Software (SaMD):** EEG analysis software is considered Software as a Medical Device (SaMD). Its classification is determined by **Rule 11** of the MDR, which links the risk class to the potential harm of an incorrect output. Software that provides information for diagnostic or therapeutic decisions is typically **Class IIa or higher** [67] [68].
A major challenge for manufacturers is the limited capacity of Notified Bodies designated to certify devices under the stricter MDR rules, which can lead to significant delays in market access.

### 5.2. AI Act: High-Risk Obligations and a Streamlined Path
The EU AI Act, with obligations for medical devices applying from **mid-2028**, will have a profound impact on AI-enabled EEG products [12].
* **High-Risk Classification:** AI systems intended for use as medical devices will be classified as "high-risk" if they require a third-party conformity assessment under the MDR (i.e., Class IIa and above) [12]. This subjects them to stringent requirements regarding risk management, data governance, transparency, human oversight, and cybersecurity [12].
* **Integrated Compliance:** To reduce the burden, the AI Act allows manufacturers to create a **single technical documentation file** that incorporates the requirements of both the MDR and the AI Act [12]. This encourages an integrated approach to compliance from the design phase.
* **CE Marking:** High-risk AI systems must bear the CE mark, affixed visibly and legibly, to be legally sold in the EU after the transition period ends [69] [70].

### 5.3. GDPR and EUDAMED: Data Governance and Traceability
* **GDPR:** EEG data is considered a "special category of personal data" under GDPR, as it qualifies as both **health data** and potentially **biometric data** [13] [71]. This mandates a high level of protection, requiring a clear legal basis for processing (such as explicit consent), data protection by design, and the completion of a **Data Protection Impact Assessment (DPIA)** for any high-risk processing [13] [72]. Techniques like pseudonymization are critical, especially for research and cross-border data transfers, which are strictly regulated under the "Schrems II" framework [73].
* **EUDAMED:** The European database for medical devices, EUDAMED, is being rolled out in modules. Mandatory registration for economic operators (manufacturers, importers) begins on **January 1, 2026**. New devices must be registered from that date, and devices already on the market must be registered by **July 1, 2026** [74]. This will create a centralized, transparent system for device traceability.

## 6. Innovation Frontier: AI & EEG Foundation Models

Europe is a vibrant hub for innovation in EEG technology, with a strong focus on applying Artificial Intelligence to solve key clinical challenges. The landscape is characterized by the emergence of commercially-approved AI products, cutting-edge academic research into foundational models, and significant public funding.

### 6.1. CE-Marked AI Products: From Lab to Clinic
Several AI-powered EEG analysis tools have successfully navigated the regulatory process and are now available on the European market, demonstrating a clear path from research to clinical adoption.

| Product / Company | Intended Use & Function | Performance & Validation |
| :--- | :--- | :--- |
| **autoSCORE (Natus Medical / Holberg EEG)** | Automated interpretation of routine clinical EEGs, classifying them as normal or abnormal (with sub-classifications) to improve efficiency and diagnostic confidence [6] [7]. | **CE-marked & FDA-cleared**. Trained on >30,000 EEGs from Norwegian and Danish centers. An external validation study showed **92%** accuracy, comparable to human experts (94%) [75] [7]. |
| **Ceribell Rapid EEG** | Point-of-care seizure detection for emergency and ICU settings. The system is designed for rapid setup and interpretation by non-specialists [1]. | Honored as a top innovative product in 2023. Focuses on addressing the critical need for immediate seizure triage in acute care [1]. |
| **BrainTrip Dementia Index (CogniScore)** | CE-marked AI tool for rapid, non-invasive dementia screening from a 30-minute EEG recording [37]. | Claims approximately **95% diagnostic accuracy**. The company is scaling in Europe with support from EIT Health [37]. |
| **NeuroCare AI Alzheimer's Tool** | AI-powered EEG system for the early detection of Alzheimer's disease [8]. | Launched in Germany in May 2024, indicating it has met initial regulatory requirements for market entry [8]. |

The success of products like autoSCORE, which was developed in a Norwegian university hospital and acquired by a major vendor, provides a powerful case study for the commercialization of clinical AI.

### 6.2. The Hunt for EEG Foundation Models
A major frontier in academic and industrial research is the development of **EEG Foundation Models (EEG-FMs)**—large, self-supervised models pre-trained on vast amounts of EEG data that can be fine-tuned for various downstream tasks like seizure detection or sleep staging [16].

While most leading EEG-FMs reviewed in 2025 were trained on US datasets like the **TUH EEG Corpus**, European research groups are highly active in this space [16]. The key challenge remains the lack of large, diverse, and well-annotated European datasets, which hinders the development of models that can generalize across different patient populations and hospital systems.

### 6.3. A Rich Funding and Research Ecosystem
Innovation is supported by a robust network of public funding and collaborative research initiatives.
* **Horizon Europe & H2020:** The EU's flagship research programs have funded numerous neurotechnology projects. A key example is **AI-Mind**, which received funding to develop AI tools for identifying dementia risk from brain connectivity patterns [76].
* **EBRAINS:** This European research infrastructure provides advanced tools, datasets, and computing resources to accelerate brain research, acting as a crucial hub for collaboration [18].
* **National Funding:** Individual member states, particularly Germany, France, and the UK, provide substantial national grants for neurotechnology and AI in healthcare research [3]. The European Commission's Digital Health Strategy has allocated **€1.2 billion** for digital health initiatives through 2027 [77].

## 7. Data Interoperability & Cybersecurity Requirements

As EEG data moves from isolated, proprietary systems to networked and cloud-based platforms, interoperability and cybersecurity have become paramount. Passing hospital procurement now requires vendors to demonstrate robust data governance and adherence to modern IT standards.

### 7.1. Emerging Standards: DICOM Waveform Displaces EDF
For decades, the **European Data Format (EDF/EDF+)** was a common standard for EEG data exchange, but its limitations—such as a lack of integrated video support and poor integration with hospital IT—have become significant drawbacks [78] [15].

The new benchmark is the **DICOM® Neurophysiology standard**, published in 2020. A pioneering clinical implementation at the Vienna Healthcare Association (WIGEV) successfully demonstrated that EEG data could be converted from proprietary formats into the DICOM standard and integrated with the hospital's existing PACS and EHR systems. This vendor-independent workflow is now recommended by leading bodies like the ILAE and IFCN, setting a new expectation for interoperability [15]. Vendors must now support DICOM-EEG export to be considered competitive.

### 7.2. Hospital Procurement: Cybersecurity is Non-Negotiable
The increasing connectivity of medical devices, coupled with rising cyber threats, has made cybersecurity a top priority for hospital procurement departments. Vendors must be prepared to meet stringent requirements that go beyond basic device function.

| Mandatory Cybersecurity & Data Governance Clauses for Hospital Tenders |
| :--- |
| **1. EU MDR & AI Act Compliance:** Proof of CE marking under MDR and a clear roadmap for AI Act compliance. |
| **2. GDPR Compliance:** A signed Data Processing Agreement (DPA) and evidence of a completed Data Protection Impact Assessment (DPIA). |
| **3. Data Encryption:** Support for strong encryption for data at rest and in transit (e.g., TLS 1.2+). |
| **4. Interoperability:** Native support for exporting data in standardized formats, with **DICOM Waveform** now preferred over EDF/EDF+. |
| **5. Integration with EMR/PACS:** Demonstrated ability to integrate with existing hospital information systems via HL7 or FHIR. |
| **6. Secure Authentication & Access Control:** Role-based access controls to ensure only authorized personnel can view patient data. |
| **7. Audit Logging:** Comprehensive and immutable logs of all access and changes to data and system settings. |
| **8. Vulnerability Management:** A clear policy for vulnerability disclosure and a Service Level Agreement (SLA) for providing security patches. |
| **9. Pseudonymization Support:** Built-in tools to pseudonymize data for research and analytics purposes. |
| **10. Secure Remote Access:** Hardened protocols for remote support and maintenance to prevent unauthorized entry points. |

## 8. Strategic Recommendations

To succeed in the dynamic European EEG market, stakeholders must adopt a multi-faceted strategy that aligns product innovation with the complex realities of reimbursement, regulation, and clinical workflow.

### 8.1. Product Roadmap: Pivot to Portable, AI-Ready, and Interoperable Systems
Manufacturers should prioritize the development of portable, wireless EEG systems with at least 32 channels, as this segment offers the highest growth and meets the demand for both clinical accuracy and remote monitoring. Every new device must be "AI-ready," with the processing power and software architecture to support current and future AI algorithms. Critically, native support for the **DICOM Neurophysiology standard** should be a core feature, not an optional add-on, to ensure seamless integration into modern hospital IT ecosystems.

### 8.2. Market Access: A Sequenced, Country-by-Country Reimbursement Strategy
A "one-size-fits-all" European launch is destined to fail. A sequenced market-access strategy is essential, starting with "beachhead" markets that offer clearer reimbursement pathways.
1. **Germany:** Leverage the **NUB process** for innovative, high-cost AI software and target DRGs where EEG is a key cost driver.
2. **France & Belgium:** Focus on securing reimbursement for ambulatory EEG using existing codes like **CCAM AAQP002** and **INAMI 477411**, and prepare dossiers for the new French add-on device pathway.
3. **Nordics & UK:** Target public tenders for tele-neurology and remote monitoring, where cloud-based platforms and service-oriented models are gaining traction.
For all other markets, a detailed analysis of regional DRG and outpatient tariff systems is required before committing significant sales resources.

### 8.3. Business Models: Embrace Partnerships and Data-Sharing
The future of EEG-AI depends on access to large, diverse datasets. Vendors should move beyond transactional device sales and embrace collaborative models. This includes forming partnerships with academic medical centers to co-develop and validate AI algorithms, as Natus did with Holberg EEG. Furthermore, creating secure, GDPR-compliant data-sharing consortia (inspired by initiatives like EBRAINS) can create a powerful competitive advantage, enabling the development of more robust and generalizable foundation models that will ultimately command higher reimbursement and wider clinical trust.

## 9. KPIs & Watch-List

To effectively gauge market traction and anticipate future shifts, stakeholders should monitor a core set of Key Performance Indicators (KPIs). These metrics provide a dashboard view of technology adoption, clinical integration, and commercial success.

| KPI & Watch-List Item | 2024 Baseline (Estimate) | 2026 Target | Rationale & Implication |
| :--- | :--- | :--- | :--- |
| **Installed Base of Portable/Ambulatory Units** | ~15,000 units | >25,000 units | Tracks the shift from hospital-centric to home/ambulatory care. A key indicator of success in the fastest-growing market segment. |
| **Annual EEG Procedure Volume per 100k Pop.** | Varies by country (e.g., ~350 in Germany) | Increase by 15% | Measures the actual clinical utilization and diagnostic throughput. Growth indicates that efficiency gains are enabling more patients to be tested. |
| **AI-Assisted Interpretation Rate** | <5% of clinical EEGs | >20% in leading hospitals | The most direct measure of AI adoption. A rising rate signals that AI is moving from novelty to standard of care, justifying premium pricing and reimbursement. |
| **New Reimbursement Code Wins** | 2-3 new national/regional codes | >8 new codes | Tracks success in navigating the reimbursement landscape. Each new code unlocks a new revenue stream and validates the technology's clinical value to payers. |
| **Reported Cybersecurity Incidents (EEG Devices)** | Low / Not publicly tracked | Maintain low numbers | A critical risk metric. Any significant incident could erode clinician and patient trust, triggering regulatory scrutiny and stalling market growth. |
| **DICOM-EEG Adoption in Tenders** | <10% of tenders | >50% of tenders | Monitors the shift towards modern interoperability standards. Vendors not supporting DICOM will be excluded from future procurement cycles. |

## References

1. *Europe Electroencephalography Devices Market | Report, ...*. https://www.grandviewresearch.com/industry-analysis/europe-electroencephalography-devices-market-report
2. *Europe Electroencephalography Devices Market Report Size, Share ...*. https://www.databridgemarketresearch.com/reports/europe-electroencephalography-devices-market?srsltid=AfmBOoqOtpVk4RWMTElScvJtP-ScRpd4MZpgk3RlxV7_x0Hz5ASJVbu8
3. *mHealth Data for Real World Evidence in Regulatory Decision ...*. https://www.ema.europa.eu/system/files/documents/report/mhealth-data-regulatory-decision-making_expert-review-report_en.pdf
4. *Electroencephalography Systems Devices Market Size & ...*. https://www.mordorintelligence.com/industry-reports/electroencephalography-systems-devices-market
5. *Europe Electroencephalography Devices Market Report Size, Share ...*. https://www.databridgemarketresearch.com/reports/europe-electroencephalography-devices-market?srsltid=AfmBOopg26y16jF7oXpy7mU5i-hZ0ahLfw8h7VTmi9YYvlJTHxXkuO1z
6. *Natus Acquires Holberg EEG, Expanding Innovation ... - PR Newswire*. https://www.prnewswire.com/news-releases/natus-acquires-holberg-eeg-expanding-innovation-in-neurodiagnostic-ai-solutions-302570347.html
7. *Automated Interpretation of Clinical Electroencephalograms ...*. https://pmc.ncbi.nlm.nih.gov/articles/PMC10282956/
8. *EEG Devices Market Size, Trends & Industry Statistics, 2032*. https://www.persistencemarketresearch.com/market-research/eeg-devices-market.asp
9. *Non-Contractual Tariffs*. https://www.royaldevon.nhs.uk/media/e1wn2w4n/foi-rdf2433-24-non-contractual-tariffs.pdf
10. *Europe Medical Device Registration (MDR, IVDR) - Kobridge*. https://kobridgeconsulting.com/europe-medical-device-registration/
11. *Medical devices classification following MDR 2017/745 - CSDmed*. https://www.csdmed.mc/en/news/medical-devices-regulation/medical-devices-classification-69
12. *Navigating the EU AI Act: implications for regulated digital medical ...*. https://pmc.ncbi.nlm.nih.gov/articles/PMC11379845/
13. *Neurodata Consent Frameworks: Managing EEG/Brain ...*. https://secureprivacy.ai/blog/neurodata-consent-eeg-brain-computer-interface-data-gdpr-ccpa
14. *Is the European Data Protection Regulation sufficient to deal with ...*. https://pmc.ncbi.nlm.nih.gov/articles/PMC8355473/
15. *DICOM® integrated EEG data: A first clinical implementation of the ...*. https://www.sciencedirect.com/science/article/abs/pii/S1388245723006934
16. *EEG Foundation Models: A Critical Review of Current ...*. https://arxiv.org/html/2507.11783v2
17. *Generalizability of electroencephalographic interpretation using ...*. https://pubmed.ncbi.nlm.nih.gov/39141002/
18. *EBRAINS: Europe's Research Infrastructure for Brain Research ...*. https://www.ebrains.eu/
19. *Europe Electroencephalography Devices Market Size | Companies*. https://www.novaoneadvisor.com/report/europe-electroencephalography-devices-market
20. *U.S. and European Patient Monitoring Equipment Market Update*. https://www.prnewswire.com/news-releases/us-and-european-patient-monitoring-equipment-market-update-remote-patient-monitoring-iot-ascs-and-the-rapid-eeg-market--idata-research-302245553.html
21. *Natus expands neurodiagnostic AI capabilities with ...*. https://www.massdevice.com/natus-expands-neurodiagnostic-ai-capabilities-holberg/
22. *Natus Medical Inc. Outlook Revised To Negative Fr - S&P Global*. https://www.spglobal.com/ratings/es/regulatory/article/-/view/type/HTML/id/3205096
23. *[PDF] NATUS MEDICAL INCORPORATED_10K_2021_V1*. https://materials.proxyvote.com/Approved/639050/20210419/AR_468383.PDF
24. *Natus Medical Incorporated - Natus*. https://natus.com/
25. *Locations - Natus Medical Incorporated*. https://natus.com/locations/
26. *[PDF] NIHON KOHDEN REPORT 2025*. https://www.nihonkohden.com/en/ir/library/ar/main/017/teaserItems3/01/linkList/0/link/NKreport2025E.pdf
27. *Products - Nihon Kohden Europe GmbH*. https://eu.nihonkohden.com/products
28. *BIS™ Monitoring System*. https://www.medtronic.com/en-us/healthcare-professionals/products/patient-monitoring/brain-monitoring/brain-channel-monitoring/bis-monitoring-system.html
29. *Medtronic achieves CE Mark approval for BrainSense™ Adaptive ...*. https://news.medtronic.com/2025-01-13-Medtronic-achieves-CE-Mark-approval-for-BrainSense-TM-Adaptive-deep-brain-stimulation-and-Electrode-Identifier,-a-groundbreaking-advance-in-personalized,-sensing-enabled-care-for-people-with-Parkinsons-through-innovative-brain-computer-interfac
30. *[PDF] ENT Catalogue 2025 - Medtronic*. https://www.medtronic.com/content/dam/medtronic-wide/public/western-europe/products/ear-nose-throat/ent-portfolio-product-catalog.pdf
31. *Enobio 8, 20, 32 | Neuroelectrics*. https://www.neuroelectrics.com/products/research/enobio
32. *EU Regulatory Framework for Medical Devices: An Introduction to ...*. https://www.neuroelectrics.com/blog/eu-regulatory-framework-for-medical-devices-an-introduction-to-mdr
33. *Entering the extension period for MDD legacy devices in the EU*. https://www.neuroelectrics.com/blog/entering-the-extension-period-for-mdd-legacy-devices-in-the-eu
34. *Neuroelectrics and Neuronostics Form Strategic Partnership to ...*. https://www.neuronostics.com/news/neuroelectrics-and-neuronostics-form-strategic-partnership-to-deliver-integrated-eeg-solutions-for-clinical-trials/
35. *mBrainTrain: Portable EEG Systems for Reseach - mbt*. https://mbraintrain.com/
36. *Advancing Brain Health with Portable EEG Systems in Europe*. https://www.medicaltechoutlook.com/news/advancing-brain-health-with-portable-eeg-systems-in-europe-nwid-3880.html
37. *AI health startups lead Europe's push for competitiveness in ...*. https://www.eit.europa.eu/news-events/news/ai-health-startups-lead-europes-push-competitiveness-healthcare-innovation
38. *Kvikna Medical Receives European Union MDR Certification*. https://stratusneuro.com/kvikna-medical-receives-european-union-mdr-certification/
39. *EEG - www.Cephalon.eu*. https://www.cephalon.eu/products/eeg-erp/
40. *A comprehensive analysis of 4 years of billing data*. https://www.sciencedirect.com/science/article/pii/S1059131125000937
41. *[PDF] Reimbursement of Medical Devices in Germany - IGES Institut*. https://www.iges.com/sites/igesgroup/iges.de/myzms/content/e29564/e30170/bitem30173/AiM_Reimbursement_of_Medical_Devices_in_Germany_2023_2024_eng.pdf
42. *OPS - BfArM*. https://www.bfarm.de/EN/Code-systems/Classifications/OPS-ICHI/OPS/_node.html
43. *OPS Version 2025 Systematisches Verzeichnis*. https://www.dkgev.de/fileadmin/default/BfArM_-_OPS_Version_2025.pdf
44. *Abschlussbericht zum aG-DRG-System 2025*. https://www.g-drg.de/content/download/14761/file/Abschlussbericht_aG-DRG_2025_2024-12-19.pdf
45. *The revised EBM catalog for the second quarter of 2025 ...*. https://mtrconsult.com/news/revised-ebm-catalog-second-quarter-2025-published-germany
46. *InEK opens the 2026 NUB proposal process - Healthcare Heads*. https://www.healthcareheads.com/en/news/news-details/inek-opens-the-2026-nub-proposal-process-2386
47. *The Institute for the Hospital Remuneration System (InEK) published ...*. https://mtrconsult.com/news/institute-hospital-remuneration-system-inek-published-2025-drg-catalog-germany
48. *National Tariff - NHS England*. https://www.england.nhs.uk/pay-syst/national-tariff/
49. *HRG4+ 2025/26 Local Payment Grouper*. https://digital.nhs.uk/services/national-casemix-office/downloads-groupers-and-tools/hrg4-2025-2026-local-payment-grouper
50. *[PDF] National Clinical Coding Standards OPCS-4 (2024)*. https://classbrowser.nhs.uk/ref_books/OPCS-4.10_NCCS-2024.pdf
51. *[XLS] 2022/23 national tariff workbook (Annex A) - NHS England*. https://www.england.nhs.uk/wp-content/uploads/2020/11/22-23NT_Annex-DtA-National-tariff-workbook.xlsx
52. *2025/26 NHS Payment Scheme – Annex B: Guidance on currencies*. https://www.england.nhs.uk/long-read/25-26-nhsps-annex-b-guidance-on-currencies/
53. *July 2025 recommendations about add-on reimbursement ... - MTRC*. https://mtrconsult.com/news/july-2025-recommendations-about-add-reimbursement-medical-devices-france
54. *New version of the CCAM Nomenclature published in France - MTRC*. https://mtrconsult.com/news/new-version-ccam-nomenclature-published-france-2
55. *[PDF] Medical practice variations - Electroencephalography*. https://www.gezondbelgie.be:6888/images/INAMI/Rapports/RAPPORT-EN-electroencephalographie_2024.pdf
56. *The first release of the DRG package for 2026 was ...*. https://mtrconsult.com/news/first-release-drg-package-2026-was-published-netherlands
57. *New NZa Reimbursement Code for Telemonitoring - Happitech*. https://happitech.com/reimbursement-code/
58. *Dutch Healthcare Authority updates in the policy framework ...*. https://mtrconsult.com/news/dutch-healthcare-authority-updates-policy-framework-small-scale-experiments-2025
59. *List of medical procedures reimbursed with restrictions updated in ...*. https://mtrconsult.com/news/list-medical-procedures-reimbursed-restrictions-updated-netherlands-0
60. *2023 version of the SwissDRG released*. https://mtrconsult.com/news/2023-version-swissdrg-released
61. *Updates of the Belgian List of reimbursable devices in June 2025*. https://mtrconsult.com/news/updates-belgian-list-reimbursable-devices-june-2025
62. *Digital Health Reimbursement Strategies of 8 European Countries ...*. https://pmc.ncbi.nlm.nih.gov/articles/PMC10576236/
63. *Common Package of Benefits updated in Spain - MTRC*. https://mtrconsult.com/news/common-package-benefits-updated-spain
64. *New national LEA tariffs will come into force in December 2024 in Italy*. https://mtrconsult.com/news/new-national-lea-tariffs-will-come-force-december-2024-italy
65. *2025 Swedish NordDRG system released - MTRC*. https://mtrconsult.com/news/2025-swedish-norddrg-system-released
66. *[PDF] MDCG 2021-24 Guidance on classification of medical devices*. https://health.ec.europa.eu/system/files/2021-10/mdcg_2021-24_en_0.pdf
67. *EU MDR Rule 11 for Software as a Medical Device - SaMD*. https://mavenprofserv.com/blog/ce-medical-device-software-samd/
68. *MDR Rule 11: Classification Rules for SaMD*. https://revolve.healthcare/blog/rule-11-mdr
69. *Article 48: CE marking | AI Act Service Desk - European Union*. https://ai-act-service-desk.ec.europa.eu/en/ai-act/article-48
70. *EU AI Act CE Mark: Why Your AI Product Dies Without It ...*. https://www.modulos.ai/blog/eu-ai-act-ce-mark-2026-deadline/
71. *[PDF] EEG-based neuroimaging under the GDPR - Brussels Privacy Hub*. https://brusselsprivacyhub.eu/onewebmedia/BPH2020%20borocz%20v1.pdf
72. *Mental data protection and the GDPR - PMC*. https://pmc.ncbi.nlm.nih.gov/articles/PMC9044203/
73. *[PDF] Guidelines 01/2025 on Pseudonymisation*. https://www.edpb.europa.eu/system/files/2025-01/edpb_guidelines_202501_pseudonymisation_en.pdf
74. *The Complete EUDAMED 2025–2026 Compliance Timeline*. https://www.ackomas.com/guide/the-complete-eudamed-2025-2026-compliance-timeline/
75. *Generalizability of electroencephalographic interpretation using ...*. https://www.researchgate.net/publication/383116116_Generalizability_of_electroencephalographic_interpretation_using_artificial_intelligence_An_external_validation_study
76. *Intelligent digital tools for screening of brain connectivity ... - CORDIS*. https://cordis.europa.eu/project/id/964220
77. *Europe EEG Headsets Market Size, Growth, Analysis & Forecast ...*. https://datahorizzonresearch.com/europe-eeg-headsets-market-50861
78. *European Data Format (EDF)*. https://www.edfplus.info/